HLS Therapeutics Balance Sheet Health
Financial Health criteria checks 3/6
HLS Therapeutics has a total shareholder equity of $82.7M and total debt of $82.4M, which brings its debt-to-equity ratio to 99.7%. Its total assets and total liabilities are $191.3M and $108.6M respectively.
Key information
99.7%
Debt to equity ratio
US$82.44m
Debt
| Interest coverage ratio | n/a |
| Cash | US$32.52m |
| Equity | US$82.71m |
| Total liabilities | US$108.62m |
| Total assets | US$191.32m |
Recent financial health updates
No updates
Recent updates
Financial Position Analysis
Short Term Liabilities: 74D's short term assets ($52.9M) exceed its short term liabilities ($26.1M).
Long Term Liabilities: 74D's short term assets ($52.9M) do not cover its long term liabilities ($82.5M).
Debt to Equity History and Analysis
Debt Level: 74D's net debt to equity ratio (60.4%) is considered high.
Reducing Debt: 74D's debt to equity ratio has increased from 50.1% to 99.7% over the past 5 years.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: Whilst unprofitable 74D has sufficient cash runway for more than 3 years if it maintains its current positive free cash flow level.
Forecast Cash Runway: 74D is unprofitable but has sufficient cash runway for more than 3 years, even with free cash flow being positive and shrinking by 1.5% per year.